Nascent Biotech is a San Diego-based company specializing in the development of innovative cancer treatments. Their flagship product, Pritumumab, is a proprietary monoclonal antibody that targets a unique antigen found on cancer cells. With FDA orphan drug status, Nascent Biotech is dedicated to delivering effective and groundbreaking therapies for cancer patients.
Through their cutting-edge research and clinical trials, Nascent Biotech aims to revolutionize cancer treatment by harnessing the power of human antibodies. Their commitment to scientific excellence and dedication to eliminating dilution risk have garnered recognition and positive analyst opinions, positioning the company as a significant player in the biotech industry.
Generated from the website